Centessa Pharmaceuticals PLC
CNTA16.420USD
-0.390-2.32%
交易中 （美東）報價延遲15分鐘
2.19B總市值
虧損本益比TTM
關於 Centessa Pharmaceuticals PLC 公司
Centessa Pharmaceuticals plc 是一家位於英國的臨牀階段製藥公司。其先進項目包括血友病項目、用於治療發作性睡病和其他睡眠-覺醒障礙的食慾素激動劑項目以及專注於其 LockBody 技術平臺的免疫腫瘤學項目。其先進候選產品 SerpinPC 是一種用於治療血友病的、處於研究階段、可能爲同類首創的皮下給藥新型活化蛋白 C 抑制劑。其食慾素受體 2 (OX2R) 激動劑項目包括 ORX750，這是一種處於研究階段的口服選擇性 OX2R 激動劑，旨在直接針對 1 型發作性睡病中食慾素神經元丟失的潛在病理生理學，並治療食慾素水平正常的睡眠-覺醒障礙，如 2 型發作性睡病和特發性嗜睡症。該公司還在探索後續食慾素激動劑，以期在一系列睡眠-覺醒障礙和更廣泛的神經系統適應症中尋找潛在的擴展機會。
公司簡介
公司代碼CNTA
公司名稱Centessa Pharmaceuticals PLC
上市日期May 28, 2021
CEODr. Saurabh Saha, M.D., Ph.D.
員工數量77
證券類型Depository Receipt
年結日May 28
公司地址3rd Floor
城市ALTRINCHAM
上市交易所NASDAQ Global Select Consolidated
國家United Kingdom
郵編WA14 2DT
電話447391789784
網址https://www.centessa.com/
公司代碼CNTA
上市日期May 28, 2021
CEODr. Saurabh Saha, M.D., Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Gregory M. (Greg) Weinhoff, M.D.
Dr. Gregory M. (Greg) Weinhoff, M.D.
Chief Business Officer
Chief Business Officer
60.24K
--
Dr. Saurabh Saha, M.D., Ph.D.
Dr. Saurabh Saha, M.D., Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
45.17K
--
Dr. Stephen J. Kanes, M.D., Ph.D.
Dr. Stephen J. Kanes, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Kristen K. Sheppard, Esq.
Mr. Kristen K. Sheppard, Esq.
Senior Vice President Investor Relations
Senior Vice President Investor Relations
--
--
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. John Crowley
Mr. John Crowley
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Karen Anderson
Ms. Karen Anderson
Chief People Officer
Chief People Officer
--
--
Ms. Tia Bush
Ms. Tia Bush
Chief Technology and Quality Officer
Chief Technology and Quality Officer
--
--
Dr. Arjun Goyal, M.D.
Dr. Arjun Goyal, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Mary Lynne Hedley, Ph.D.
Dr. Mary Lynne Hedley, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Gregory M. (Greg) Weinhoff, M.D.
Dr. Gregory M. (Greg) Weinhoff, M.D.
Chief Business Officer
Chief Business Officer
60.24K
--
Dr. Saurabh Saha, M.D., Ph.D.
Dr. Saurabh Saha, M.D., Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
45.17K
--
Dr. Stephen J. Kanes, M.D., Ph.D.
Dr. Stephen J. Kanes, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Kristen K. Sheppard, Esq.
Mr. Kristen K. Sheppard, Esq.
Senior Vice President Investor Relations
Senior Vice President Investor Relations
--
--
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. John Crowley
Mr. John Crowley
Chief Financial Officer
Chief Financial Officer
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 7月2日 週三
更新時間: 7月2日 週三
持股股東
股東類型
持股股東
持股股東
佔比
Medicxi Ventures (UK) LLP
14.94%
Index Ventures SA
7.46%
General Atlantic LLC
7.25%
Adage Capital Management, L.P.
5.20%
Janus Henderson Investors
4.43%
Other
60.72%
持股股東
持股股東
佔比
Medicxi Ventures (UK) LLP
14.94%
Index Ventures SA
7.46%
General Atlantic LLC
7.25%
Adage Capital Management, L.P.
5.20%
Janus Henderson Investors
4.43%
Other
60.72%
股東類型
持股股東
佔比
Hedge Fund
23.53%
Venture Capital
23.05%
Investment Advisor
19.40%
Investment Advisor/Hedge Fund
15.34%
Private Equity
10.46%
Research Firm
2.54%
Individual Investor
0.50%
Endowment Fund
0.06%
Other
5.12%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
220
133.64M
100.03%
-11.01M
2025Q1
222
135.75M
101.62%
-10.84M
2024Q4
187
130.97M
99.33%
-6.00M
2024Q3
166
123.88M
97.57%
+8.26M
2024Q2
145
101.97M
89.71%
-3.69M
2024Q1
140
90.07M
89.09%
-8.60M
2023Q4
126
85.94M
86.60%
-9.82M
2023Q3
125
84.37M
86.02%
-11.03M
2023Q2
135
82.21M
85.98%
-8.96M
2023Q1
131
78.75M
82.92%
-8.68M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Medicxi Ventures (UK) LLP
19.96M
14.94%
--
--
Apr 24, 2025
Index Ventures SA
9.96M
7.46%
--
--
Apr 24, 2025
General Atlantic LLC
9.68M
7.25%
--
--
Apr 24, 2025
Adage Capital Management, L.P.
6.95M
5.2%
+1.83M
+35.85%
Mar 31, 2025
Janus Henderson Investors
5.92M
4.43%
+1.01M
+20.63%
Mar 31, 2025
T. Rowe Price Associates, Inc.
5.34M
4%
-22.05K
-0.41%
Mar 31, 2025
First Light Asset Management, LLC
4.87M
3.65%
-931.06K
-16.04%
Mar 31, 2025
Farallon Capital Management, L.L.C.
4.33M
3.24%
+835.61K
+23.88%
Mar 31, 2025
Avoro Capital Advisors LLC
4.05M
3.03%
+4.05M
--
Mar 31, 2025
VV Manager LLC
3.93M
2.95%
--
--
Dec 31, 2024
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Virtus LifeSci Biotech Clinical Trials ETF
0.98%
ProShares Ultra Nasdaq Biotechnology
0.14%
Invesco Nasdaq Biotechnology ETF
0.14%
SPDR S&P International Small Cap ETF
0.09%
iShares Biotechnology ETF
0.07%
T Rowe Price Small-Mid Cap ETF
0.05%
Fidelity Nasdaq Composite Index ETF
0%
First Trust IPOX Europe Equity Opportunities ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.98%
ProShares Ultra Nasdaq Biotechnology
佔比0.14%
Invesco Nasdaq Biotechnology ETF
佔比0.14%
SPDR S&P International Small Cap ETF
佔比0.09%
iShares Biotechnology ETF
佔比0.07%
T Rowe Price Small-Mid Cap ETF
佔比0.05%
Fidelity Nasdaq Composite Index ETF
佔比0%
First Trust IPOX Europe Equity Opportunities ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
